[Insulin secretion after oral and intravenous administration of various 1st and 2d generation sulfonylurea derivatives in equipotential dosage].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to E Haupt.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Approximately 5-20% of patients with hemophilia A acquire antifactor VIII antibodies during transfusion therapy. These autoantibodies cause serious bleeding and are rarely found in non hemophiliac patients (only a few hundred case reports in the literature). Treatment of this autoimmune condition is quite difficult: corticosteroids, immunosuppressive agents, plasmapheresis and transfusions may be useful. We describe two patients we observed and add some general reflections on therapy.
In a double-blind cross-over trial on 20 diabetic patients of type IIb we investigated whether a drug interaction between glibenclamide and acemetacin may possibly occur. After hospitalization of all in-patients needing glibenclamide therapy, a one-week period of adaptation to clinical conditions with optimized diet, antidiabetic dosage of the drug and the beginning of a diabetes learning programme followed. Thereafter, in a randomized design, ten out of the 20 patients were treated concomitantly with either 60 mg acemetacin t.i.d. or placebo for 1 week. Furthermore, a cross-over period of one week's duration followed once more. Daily blood glucose profiles (four values) were measured every second day and suggested a continuous improvement of the severe diabetic state previously seen. Blood glucose levels reached an optimal steady-state condition after 1 week of adaptation. Concomitant treatment with acemetacin did not lead to a relevant alteration of the laboratory parameters used in type IIb diabetic patients. This could also be established due to HbA1 values. Contrary to other nonsteroidal anti-inflammatory drugs, interactions between acemetacin and the widely used oral antidiabetic glibenclamide could not be established.